Hematopoietic Stem Cell Transplantation-associated Thrombotic Microangiopathy
📧 Sign up to get email alerts when something new happens for Hematopoietic Stem Cell Transplantation-associated Thrombotic Microangiopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: Study of Ravulizumab in Pediatric Participants With HSCT-TMA [Phase 3]
A Phase 3 trial evaluating Ravulizumab in pediatric participants with hematopoietic stem cell transplantation-associated thrombotic microang…
-
FDA approval · 2025-12-23FDA Approved: YARTEMLEA — Original Application (Omeros Corporation)
FDA approved the original biologics license application for narsoplimab (brand YARTEMLEA) from Omeros Corporation for hematopoietic stem cel…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 4]
Phase 4 pharmacokinetic study of Thymoglobulin in patients undergoing hematopoietic stem cell transplantation, focusing on HSCT-associated t…